PharmaCyte Biotech Inc Working Capital to Net Assets Ratio
PharmaCyte Biotech Inc working capital to net assets ratio. PharmaCyte Biotech Inc (PMCB) has a Working Capital to Net Assets ratio of 104.6% as of April 2026. Working capital of $36.59 Million (current assets of $37.42 Million minus current liabilities of $826.42K) is measured against net assets of $34.98 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check PMCB tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of PharmaCyte Biotech Inc (2004–2026)
Working capital to net assets ratio of PharmaCyte Biotech Inc from 2004 to 2026. This chart shows how PharmaCyte Biotech Inc's Working Capital to Net Assets ratio has evolved across 23 annual periods from 2004 to 2026. As of April 2026, the ratio stands at 104.6%, reflecting working capital of $36.59 Million against net assets of $34.98 Million USD. See PharmaCyte Biotech Inc (PMCB) liquidity interval to measure how many days the company can operate on defensive assets alone.
PharmaCyte Biotech Inc Working Capital to Net Assets Ratio by Year (2004–2026)
PharmaCyte Biotech Inc working capital to net assets ratio by year from 2004 to 2026. The table below presents the year-by-year Working Capital to Net Assets ratio for PharmaCyte Biotech Inc from 2004 to 2026, covering 23 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see PharmaCyte Biotech Inc assets under control.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 104.6% | $36.59 Million | $34.98 Million | $37.42 Million | $826.42K | ▲ +67.1 pp |
| 2025 | 37.5% | $19.46 Million | $51.89 Million | $22.38 Million | $2.91 Million | ▼ -71.4 pp |
| 2024 | 108.9% | $43.02 Million | $39.51 Million | $50.44 Million | $7.42 Million | ▲ +15.9 pp |
| 2023 | 92.9% | $67.56 Million | $72.69 Million | $68.15 Million | $586.58K | ▼ -1.4 pp |
| 2022 | 94.3% | $84.79 Million | $89.92 Million | $85.49 Million | $704.37K | ▲ +71.1 pp |
| 2021 | 23.2% | $1.55 Million | $6.68 Million | $2.28 Million | $724.78K | ▲ +23.1 pp |
| 2020 | 0.1% | $6.25K | $5.09 Million | $1.04 Million | $1.03 Million | ▲ +1.9 pp |
| 2019 | -1.8% | $-89.45K | $5.04 Million | $653.40K | $742.85K | ▼ -12.9 pp |
| 2018 | 11.1% | $639.70K | $5.77 Million | $1.28 Million | $644.17K | ▼ -25.5 pp |
| 2017 | 36.6% | $2.96 Million | $8.09 Million | $3.54 Million | $580.25K | ▲ +15.2 pp |
| 2016 | 21.4% | $1.39 Million | $6.52 Million | $2.03 Million | $637.64K | ▲ +7.8 pp |
| 2015 | 13.6% | $806.58K | $5.94 Million | $2.82 Million | $2.01 Million | ▼ -29.1 pp |
| 2014 | 42.6% | $3.81 Million | $8.94 Million | $4.19 Million | $373.67K | ▼ -169.0 pp |
| 2013 | 211.6% | $-1.95 Million | $-921.46K | $1.85 Million | $3.80 Million | ▲ +51.1 pp |
| 2012 | 160.5% | $-2.73 Million | $-1.70 Million | $1.06 Million | $3.79 Million | ▲ +40.2 pp |
| 2011 | 120.4% | $-3.28 Million | $-2.73 Million | $104.75K | $3.39 Million | ▼ -35.4 pp |
| 2010 | 155.8% | $-3.04 Million | $-1.95 Million | $13.68K | $3.05 Million | ▲ +147.7 pp |
| 2009 | 8.1% | $252.84K | $3.12 Million | $1.18 Million | $929.89K | ▼ -39.7 pp |
| 2008 | 47.8% | $3.55 Million | $7.44 Million | $3.74 Million | $180.56K | ▼ -29.5 pp |
| 2007 | 77.3% | $3.31 Million | $4.29 Million | $3.43 Million | $118.81K | ▲ +8.8 pp |
| 2006 | 68.5% | $3.02 Million | $4.41 Million | $3.13 Million | $106.21K | ▲ +62.0 pp |
| 2005 | 6.5% | $-84.77K | $-1.30 Million | $212.68K | $297.45K | ▲ +91.6 pp |
| 2004 | -85.0% | $130.45K | $-153.43K | $130.71K | $260.00 | — |